Citron Research: Don't Expect Anything Earth-Shattering on Valeant (VRX) Come Monday
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Valeant Pharma (VRX) Issues Dear Doctor Letter; Philidor Issues Release - Evercore ISI
November 2, 2015 9:04 PM ESTEvercore ISI analyst Umer Raffat noted two new developments in the Valeant Pharma (NYSE: VRX) saga. First the company sent a dear doctor letter to dermatologists and separately, Philidor issued a press release.
Raffat highlighted the following from the letter:
For... MoreDead Cat Bounce, Or is a Sustainable Relief Rally in Store for Valeant (VRX)?
November 2, 2015 3:17 PM ESTCitron Research founder Andrew Left's decision to step back from publishing incremental negative research on Valeant (NYSE: VRX) does absolutely nothing to change the fact that there are things we simply don't know about the company's financials, however it does temporarily remove the threat of death by 1000 tweets. This could open the door for analysts who had been supportive of the company... More
Citron Research: Not Dialing Back Warning on Valeant Pharma (VRX), Dialing Back on Citron Focus
November 2, 2015 10:02 AM EST(Updated - November 2, 2015 10:06 AM EST)
Citron Research: Not dialing back warning on Valeant Pharma (NYSE: VRX), instead they are dialing back the focus on Citron to investigate and report the vast spectrum of claims now piling up against the company.
Citron said "For those of you expecting a kill shot, you can stop reading here."
Citron said the stock is uninvestible for the foreseeable future.
Citron provided the following list of some but not all of the immediate concerns facing Valeant and its shareholders:
1) Valeants civil and criminal culpability... More
Valeant Pharma (VRX) Ticks Higher as Short Seller Softens Further Allegations
November 2, 2015 9:25 AM ESTValeant Pharmaceuticals (NYSE: VRX) shares are ticking higher Monday as one pundit on the stock opted to back off from issuing fierce commentary about the company's operations.
As... More
Valeant Pharmaceuticals (VRX) PT, Estimates Cut at Jefferies after Dropping Philidor
November 2, 2015 7:18 AM ESTJefferies analyst David Steinberg lowered estimates and his price target on Valeant Pharmaceuticals (NYSE: VRX) to $172.00 (from $224.00) after the company dropped Philidor but maintained a Buy rating.
commented, "VRX severed ties with Philidor following allegations of improper business conduct and intense... More
Valeant Pharma (VRX) Trades Near Lows Heading Into Weekend
October 30, 2015 3:23 PM EDTValeant Pharma (NYSE: VRX) fell to session lows in the final hour of trading. Earlier Citron said it plans to update its short report on Monday, claiming the company is "dirtier than has been reported." Concerns about the possible release of new information set... More
Bill Ackman's conference call on Valeant Pharma (VRX) ends
October 30, 2015 1:01 PM EDTBill Ackman's conference call on Valeant Pharma (NYSE: VRX) ends
... MoreValeant Pharmaceuticals (VRX) Bull-Bear Debate Rages
October 30, 2015 12:57 PM EDTThe bull-bear battle in beaten up and highly-questioned Valeant Pharma (NYSE: VRX) took center stage again today. Bill Ackman from Pershing Square on the bull side and Andrew Left from Citron Research on the bear side. Currently the bears are winning and the stock is down another 10% today and again below the $100 level.
This morning the company announced that it is severing all ties with Philidor Rx and Philidor has informed Valeant that it will shut down operations as soon as possible. Valeant's controversial... More
Citron's Left Will be on CNBC Monday to Talk About Valeant (VRX)
October 30, 2015 12:27 PM EDTCitron's Andrew Left will be back on CNBC's Halftime Report on Monday, November 2nd, to talk about his upcoming report on Valeant Pharma (NYSE: VRX).
... MoreStreetinsider.com's Hot Lunchtime Reads 10/30: (VRX) (AAPL) (ON) (MGM)
October 30, 2015 12:15 PM EDTThe following is a list of notable articles to help get you through the lunch hour:Citron Research says Valeant Pharma (VRX) has better chance than HLF of 'going to $0' ->... More
Valeant Pharma (VRX) falls below $100 again
October 30, 2015 11:58 AM EDTValeant Pharma (NYSE: VRX) falls below $100 again
... MoreCitron tweets Valeant has better chance of going to zero than Herbalife ever will
October 30, 2015 11:47 AM EDTNEW YORK (Reuters) - Influential short-seller Citron Research tweeted Friday that the shares of Valeant Pharmaceuticals International (NYSE: VRX) have a better chance of going to zero than Herbalife Ltd (NYSE: HLF).
Citron... More
Citron Research says Valeant Pharma (VRX) has better chance than HLF of 'going to $0'
October 30, 2015 11:26 AM EDTCitron Research says Valeant Pharma (NYSE: VRX) has better chance than HLF of 'going to $0'. Citron said it will have more details on Monday. Calls company 'dirtier' than anyone has reported.
... More
Bill Ackman said their average cost on Valeant Pharma (VRX) is $186
October 30, 2015 11:11 AM EDTOn Valeant Pharma (NYSE: VRX) call, Bill Ackman said their average cost is $186
... More